Enlivex (ENLV) Other Accumulated Expenses (2017 - 2025)
Enlivex (ENLV) posted quarterly Other Accumulated Expenses of $1.9 million for Q4 2025, up 104.11% year-over-year from $925000.0 in Q4 2024, and up 163.69% quarter-over-quarter from $716000.0 in Q2 2025.
Enlivex (ENLV) Other Accumulated Expenses (2017 - 2025) Analysis & Trends
Enlivex's Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.9 million for Q4 2025.
- In Q4 2025, Other Accumulated Expenses rose 104.11% year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $1.9 million (up 104.11% YoY), while the FY2025 annual figure was $1.9 million, up 104.11% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $1.9 million, up from $716000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $2.7 million in Q4 2022, with the low at $716000.0 in Q2 2025.
- The 5-year median for Other Accumulated Expenses is $1.7 million (2022), against an average of $1.7 million.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses tumbled 60.54% in 2024, then surged 104.11% in 2025.
- Enlivex's Other Accumulated Expenses stood at $1.6 million in 2021, then soared by 65.53% to $2.7 million in 2022, then fell by 13.44% to $2.3 million in 2023, then sank by 60.54% to $925000.0 in 2024, then soared by 104.11% to $1.9 million in 2025.
- Business Quant data shows ENLV's Other Accumulated Expenses at $1.9 million in Q4 2025, $716000.0 in Q2 2025, and $925000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.89 Mn |
| Jun 30, 2025 | 716,000.00 |
| Dec 31, 2024 | 925,000.00 |
| Jun 30, 2024 | 1.60 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Jun 30, 2022 | 1.64 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Jun 30, 2021 | 2.08 Mn |
| Dec 31, 2020 | 1.50 Mn |
| Jun 30, 2020 | 1.32 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2018 | 575,000.00 |
| Dec 31, 2017 | 157,000.00 |